Optomed Plc Interim Report, January – March 2022
Optomed Plc: Interim Report, January – March 2022
January – March 2022
- Revenue decreased by 18.5 percent to EUR 3.2 (3.9) million
- Devices segment revenue decreased by 26.5 % to EUR 1.1 (1.4) million
- Software segment revenue decreased by 13.9 % to EUR 2.2 (2.5) million against the strong comparison period
- EBITDA amounted to EUR -937 (-315) thousand corresponding to -29.2 (-8.0) percent of revenue
- In the Devices segment, the revenue from China declined over 90% whereas the rest of the world grew over 50%. The key driver for the decline in China was the changes communicated in February
- Optomed announced the results from the prospective, multi-center clinical trial intended to assess its handheld fundus camera Aurora together with AEYE Health’s AI for autonomous detection of more than mild diabetic retinopathy
Key figures
| EUR, thousand | Q1/2022 | Q1/2021 | Change, % | 2021 |
| Revenue | 3,214 | 3,944 | -18.5% | 14,850 |
| Gross profit * | 2,190 | 2,577 | -15.0% | 10,558 |
| Gross margin % * | 68.1% | 65.3% | 71.1% | |
| EBITDA | -937 | -315 | -197.9% | -2,002 |
| EBITDA margin *, % | -29.2% | -8.0% | -13.5% | |
| Adjusted EBITDA * | -937 | -315 | -197.9% | -2,002 |
| Adjusted EBITDA margin *, % | -29.2% | -8.0% | -13.5% | |
| Operating result (EBIT) | -1,461 | -851 | -71.7% | -4,780 |
| Operating margin (EBIT) *, % | -45.4% | -21.6% | -32.2% | |
| Adjusted operating result (EBIT) * | -1,461 | -851 | -71.7% | -4,780 |
| Adjusted operating margin (EBIT margin) *, % | -45.4% | -21.6% | -32.2% | |
| Net profit/ loss | -1,370 | -616 | -122.5% | -4,249 |
| Earnings per share | -0.10 | -0.05 | -101.6% | -0.32 |
| Cash flow from operating activities | -688 | -257 | -75.4% | -2,940 |
| Net Debt | 1,821 | -3,416 | -153.3% | 213 |
| Net debt/ Adjusted EBITDA (LTM) | -0.7 | 7.2 | -0.1 | |
| Equity ratio * | 57.9% | 64.2% | 58.8% | |
| R&D expenses personnel | 376 | 479 | -21.4% | 1,773 |
| R&D expenses other costs | 209 | 149 | 40.1% | 511 |
| Total R&D expenses | 585 | 628 | -6.8% | 2,284 |
*) Alternative performance measures, see section Alternative Performance Measures for definitions and calculations.
CEO comments
Significant growth expectations in the US market, China market remains difficult to forecast. Global demand for screening and artificial intelligence solutions is growing. The first half of the year is expected to be weak, the second half looks strong.
Revenue decreased by 18.5 percent in the first quarter. The main reason for this negative trend in sales was low camera sales to China compared to a relatively high comparison period last year. In addition, no significant new software deliveries occurred in the first quarter. The weakened covid-19 situation and the consequent large-scale lockdowns significantly complicated sales and marketing work, as well as building new distribution channels in China. In addition, the war in Ukraine is currently having some negative effects on the business of both segments. However, the impact of the war on our full-year revenue is expected to be relatively small.
The most significant event of the quarter was the completion of the clinical trial of our Aurora AEYE product in the United States and the publication of the results. The study was arranged by our strategic artificial intelligence partner AEYE Health that is also responsible for the FDA application process. We were very pleased with the results of the study, and we are now in our view able to move forward with our FDA clearance process, which is our main strategic goal for the year. The transformation of the diabetic retinopathy screening market in the United States is now getting started with the establishment of the new reimbursement code (CPT 92229), and Optomed will be in a unique position if our FDA clearance process is successful. Optomed’s AI-based screening solution business model in the US will be a continuous revenue model based on a monthly fee, and the company will aim to gain a significant share of the US diabetic retinopathy screening market.
The United States, Western Europe and Asia markets excluding China continued to develop well. The demand for screening solutions together with artificial intelligence has clearly increased over the past six months. Optomed currently has several new pilots and sales projects around the world that are expected to materialize into major solution deliveries in the future, including both hardware and software. We see this positive development as a sign of a general market recovery from the covid-19 pandemic.
Because of low camera sales in China, the first half of the year is expected to be weak, but starting from the second half our outlook looks strong due to the positive development trends in the US and other Western markets. In addition, our major product development projects, which have been ongoing for years, will be completed by the end of the year and we aim to introduce new products to the market in 2022 and 2023. This will be reflected in lower product development costs from the second half of the year onwards. We expect these new products to contribute to accelerating the company’s revenue growth significantly in the coming years. Currently, we are strongly prioritizing the development of our Aurora-AEYE solution which will be reflected as slightly lower revenue from other software deliveries during 2022.
Seppo Kopsala,
CEO
Outlook 2022
Optomed expects its full year 2022 revenue to grow compared to 2021.
Telephone conference
A telephone conference for analysts, investors and media will be arranged on 5 May 2022 at 11.00 EEST. The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EEST at the latest.
The participants are requested to register for the call-in advance by email to sakari.knuutti@optomed.com.
Please see the call-in numbers below:
FI +358 9 856 263 00
SE +46 8 505 218 52
UK +44 20 3321 5273
US +1 646 838 1719
FR +33 1 70 99 53 92
The conference id is 924 665 869#.
Please note that by dialing into the conference call, the participant agrees that personal information such as name and company name will be collected.
Group performance
January – March 2022
In January-March 2022, Group revenue decreased by 18.5 percent to EUR 3,214 (3,944) thousand. The main reason for the decline was the earlier communicated changes in China impacting camera sales. This was partly compensated by continued growth in Western markets, especially Europe and the USA. The Devices segment’s revenue decreased by 26.5 percent as the revenue from China declined over 90% whereas the rest of the world grew over 50%. The Software segment’s revenue decreased by 13.9 percent against the strong comparison period The decline was partly compensated by recurring revenue growth from existing customers.
The Group gross margin was 68.1 (65.3) percent. The Group recorded other operating income of EUR 36 (82) thousand during January-March. The gross margin excluding other operating income was 67.0 percent in 2022 and 63.3 percent in 2021.
In January-March 2022, Group reported EBITDA amounted to EUR -937 (-315). The main reason for the negative EBITDA development compared to 2021 was lower revenue.
In January-March 2022, net financial items amounted to EUR 71 (216) thousand and consisted mainly of interest payments to financial institutions and the translation effect of Chinese RMB and USD to EUR.
Cash flow and financial position
January – March 2022
In January-March 2022, the cash flow from operating activities amounted to EUR -688 (-257) thousand. Net cash in investing activities was EUR -859 (-557) thousand and relates mainly to capitalized development expenses. Net cash from financing activities amounted to EUR -622 (-71).
Consolidated cash and cash equivalents at the end of the period amounted to EUR 4,630 (9,767) thousand. Interest-bearing net debt totaled EUR 1,821 (-3,416) thousand at the end of the period.
Net working capital was EUR 4,115 (3,689) thousand at the end of the period.
Devices segment
Optomed has two synergistic business segments: Devices and Software.
The Devices segment develops, commercializes, and manufactures easy-to-use, and affordable handheld fundus cameras, that are suitable for any clinic for screening of various eye diseases, such as diabetic retinopathy, glaucoma, and AMD (Age Related Macular Degeneration).
| EUR, thousand | Q1/2022 | Q1/2021 | Change, % | 2021 |
| Revenue | 1,065 | 1,447 | -26.5 % | 5,839 |
| Gross profit * | 641 | 842 | -23.9 % | 4,139 |
| Gross margin, % * | 60.2% | 58.2% | 70.9% | |
| EBITDA | -499 | -231 | -116.3 % | -1,014 |
| EBITDA margin, % * | -46.9% | -15.9% | -17.4% | |
| Operating result (EBIT) | -864 | -615 | -40.6 % | -3,182 |
| Operating margin (EBIT), % * | -81.1% | -42.5% | -54.5% |
*) Alternative performance measures, see section Alternative Performance Measures for definitions and calculations.
January – March 2022
In January-March 2022, the Devices segment revenue decreased by 26.5 percent and was EUR 1,065 (1,447) thousand. The negative growth was mainly due to changes in China, which were communicated in February, impacting camera sales. This was partly compensated by continued growth in Western markets, especially in Europe and the USA. The revenue from China declined over 90% whereas the rest of the world grew over 50%. China market remains difficult to forecast due to covid19 pandemic.
In January-March 2022, the gross margin increased to 60.2 percent from 58.2 percent in the previous year.
In January-March 2022 EBITDA was EUR -499 (-231) thousand or -46.9 (-15.9) percent of revenue. The key driver for the lower EBITDA was lower revenue.
Software segment
Optomed has two synergistic business segments: Devices and Software.
The Software segment develops and commercializes screening software for diabetic retinopathy and cancer screening for healthcare organizations. The segment also distributes off-the-shelf products from selected partners to supplement its own solutions and expertise and provides software consultation to support the Devices segment screening solution projects.
| EUR, thousand | Q1/2022 | Q1/2021 | Change, % | 2021 |
| Revenue | 2,150 | 2,497 | -13.9 % | 9,011 |
| Gross profit * | 1,549 | 1,734 | -10.7 % | 6,420 |
| Gross margin, % * | 72.0 % | 69.5% | 71.2% | |
| EBITDA | 414 | 540 | -23.3 % | 1,855 |
| EBITDA margin, % * | 19.3 % | 21.6% | 20.6% | |
| Operating result (EBIT) | 257 | 388 | -33.7 % | 1,247 |
| Operating margin (EBIT), % * | 12.0 % | 15.5% | 13.8% |
*) Alternative performance measures, see section Alternative Performance Measures for definitions and calculations.
January – March 2022
In January-March 2022, the Software segment revenue decreased by 13.9 percent and was EUR 2,150 (2,497) thousand against the strong comparison period as no large software delivery projects were completed during the quarter. The decline was partly compensated by the continued stable recurring business from the current customer base. In January-March 2022, the gross margin was 72.0 (69.5) percent.
EBITDA was EUR 414 (540) thousand or 19.3 (21.6) percent of revenue, respectively. The key driver for the lower EBITDA was lower revenue.
Group-wide expenses
Group-wide expenses relate to functions supporting the entire group such as treasury, group accounting, Marketing, legal, HR, and IT.
January – March 2022
In January-March 2022, group-wide operating expenses amounted to EUR 853 (624) thousand. The increase is mainly related to strengthened of Group Marketing function in second half of 2021.
Personnel
Number of personnel at the end of the reporting period.
| 31 March 2022 | 31 March 2021 | |
| Devices | 53 | 57 |
| Software | 45 | 40 |
| Group | 23 | 18 |
| Total | 121 | 114 |
Corporate Governance
Optomed complies with Finnish laws and regulations, Optomed’s Articles of Association, the rules of Nasdaq Helsinki and the Finnish Corporate Governance Code 2021 issued by the Securities Market Association of Finland. The code is publicly available at http://cgfinland.fi/en/. Optomed’s corporate governance statement 2021 is available on the company website www.optomed.com/investors/.
Annual General Meeting
Optomed’s Annual General Meeting will be held at Life Science Center, Keilaranta 16 B, FI-02150, Espoo, Finland on 10 May 2022. The registration period and advance voting period commenced on 14 April 2022 at 10:00 a.m. (EEST) and ended on 3 May 2022 at 4:00 p.m. (EEST). Shareholders and their proxy representatives can only participate in the meeting and use shareholders’ rights by voting in advance as well as by posing counterproposals and questions in advance. The invitation and other material is available at https://www.optomed.com/investors/annual-general-meeting-2022/
Shares and shareholders
The company has one share series with all shares having the same rights. At the end of the review period Optomed Plc’s share capital consisted of 14,003,144 shares and the company held 406,217 shares in the treasury which corresponds approximately 2.9 percent of the total amount of the shares and votes. Additional information with respect to the shares, shareholding and trading can be found on the company’s website www.optomed.com/investors/.
Risks and uncertainties
The key risks and uncertainties are described in the company’s Annual Report 2021 which was published on 4 March 2022. The complete report is available at https://www.optomed.com/investors/. The risk position of Optomed has not changed since then.
Flagging notifications
26 January 2022, the total holding in Optomed shares and votes held by BIAM has decreased to 4.31 % of all of the registered shares in Optomed.
Events after the review period
No material events after the reporting period.
Audit review
This financial report has not been audited by the company’s auditors.
Financial reporting in 2022
4 August 2022 – Half-Year Financial Report for 1 January – 30 June 2022
3 November 2022 – Interim Report for 1 January – 30 September 2022
For more information, contact
Lars Lindqvist, CFO
Tel: +46 702 59 57 89
E-mail: lars.lindqvist@optomed.com
Seppo Kopsala, CEO
Tel.: +358 40 555 1050
E-mail: seppo.kopsala@optomed.com
About Optomed
Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company’s products are sold via various sales channels in over 60 countries globally.
Alternative Performance Measures
Optomed uses certain alternative performance measures (APMs) with the purpose to provide a better understanding of how the business develops. These APMs, as defined, cannot be fully compared with other companies’ APMs.
| Alternative Performance Measures | Definition | |
| Gross profit | Revenue + Other operating income – Materials and services expenses | |
| Gross margin, % | Gross profit / Revenue | |
| EBITDA | Operating result before depreciation, amortization, and impairment losses | |
| EBITDA margin, % | EBITDA / Revenue | |
| Operating result | Profit/loss after depreciation, amortization, and impairment losses | |
| Operating margin, % | Operating result / Revenue | |
| Adjusted operating result | Operating result excluding items affecting comparability | |
| Adjusted operating margin, % | Adjusted operating result / Revenue | |
| Adjusted EBITDA | EBITDA excluding items affecting comparability | |
| Adjusted EBITDA margin % | Adjusted EBITDA / Revenue | |
| Items affecting comparability | Material items outside ordinary course of business including restructuring costs, net gains or losses from sale of business operations or other non-current assets, strategic development projects, external advisory costs related to capital reorganization, impairment charges on non-current assets incurred in connection with restructurings, compensation for damages and transaction costs related to business acquisitions. | |
| Net Debt | Interest-bearing liabilities (borrowings from financial institutions, government loans and subordinated loans) – cash and cash equivalents (excl. lease liabilities according to IFRS 16) | |
| Net Debt / Adjusted EBITDA (LTM), times | Net Debt / Adjusted EBITDA (for the last twelve months, LTM) | |
| Earnings per share | Net result / Number of outstanding shares (reflecting changes in the number of shares following the resolution of the EGM to split the shares of the company with a ratio of 1:20) | |
| Equity ratio, % | Total equity / Total assets | |
| R&D expenses | Employee benefit expenses for R&D personnel and other operational expenses related to R&D activities | |
Consolidated income statement
| In thousands of euro | Q1/2022 | Q1/2021 | 2021 |
| Revenue | 3,214 | 3,944 | 14,850 |
| Other operating income | 36 | 82 | 810 |
| Materials and services | -1,061 | -1,449 | -5,102 |
| Employee benefit expenses | -2,243 | -2,148 | -8,702 |
| Depreciation, amortization, and Impairment losses | -524 | -536 | -2,778 |
| Other operating expenses | -884 | -744 | -3,858 |
| Operating result | -1,461 | -851 | -4,780 |
| Finance income | 116 | 239 | 715 |
| Finance expenses | -45 | -23 | -263 |
| Net finance expenses | 71 | 216 | 453 |
| Profit (loss) before income taxes | -1,390 | -635 | -4,327 |
| Income tax expense | 20 | 19 | 78 |
| Loss for the period | -1,370 | -616 | -4,249 |
| Loss for the period attributable to | |||
| Owners of the parent company | -1,370 | -616 | -4,249 |
| Loss per share attributable to owners of the parent company | |||
| Weighted average number of shares | 13,591,827 | 13,326,099 | 13,441,437 |
| Basic loss per share (euro) | -0.10 | -0.05 | -0.32 |
Consolidated condensed comprehensive income statement
| In thousands of euro | Q1/2022 | Q1/2021 | 2021 |
| Loss for the period | -1,370 | -616 | -4,249 |
| Other comprehensive income | |||
| Foreign currency translation difference | -77 | -78 | -253 |
| Other comprehensive income, net of tax | -77 | -78 | -253 |
| Total comprehensive income for the period | –1,447 | -694 | -4,502 |
| Total comprehensive loss attributable to Owners of the parent company | -1,447 | -694 | -4,502 |
Consolidated balance sheet
| In thousands of euro | March 31 2022 | March 31 2021 | Dec 31, 2021 |
| ASSETS | |||
| Non-current assets | |||
| Goodwill | 4,256 | 4,256 | 4,256 |
| Development costs | 6,623 | 5,842 | 6,338 |
| Customer relationships | 1,330 | 1,552 | 1,386 |
| Technology | 611 | 712 | 636 |
| Other intangible assets | 358 | 454 | 358 |
| Total intangible assets | 13,177 | 12,816 | 12,975 |
| Tangible assets | 667 | 399 | 433 |
| Right-of-use assets | 1,101 | 1,091 | 1,205 |
| Deferred tax assets | 13 | 11 | 13 |
| Total non-current assets | 14,959 | 14,317 | 14,626 |
| Current assets | |||
| Inventories | 3,260 | 2,353 | 2,936 |
| Trade and other receivables | 4,247 | 4,410 | 4,631 |
| Cash and cash equivalents | 4,630 | 9,767 | 6,804 |
| Total current assets | 12,136 | 16,530 | 14,371 |
| Total assets |
27,096
|
30,847 | 28,998 |
| In thousands of euro | March 31 2022 | March 31 2021 | Dec 31, 2021 |
| EQUITY | |||
| Share capital | 80 | 80 | 80 |
| Share premium | 504 | 504 | 504 |
| Reserve for invested non-restricted equity | 38,579 | 37,708 | 38,526 |
| Translation differences | -164 | 88 | -88 |
| Retained earnings | -21,933 | -17,950 | -17,721 |
| Profit (loss) for the financial year | -1,370 | -616 | -4,249 |
| Total equity | 15,696 | 19,813 | 17,052 |
| LIABILITIES | |||
| Non-current liabilities | |||
| Borrowings from financial institutions | 3,646 | 3,299 | 3,813 |
| Government loans | 1,908 | 2,336 | 1,940 |
| Lease liabilities | 721 | 699 | 818 |
| Deferred tax liabilities | 444 | 521 | 463 |
| Total Non-current liabilities | 6,719 | 6,855 | 7,034 |
| Current liabilities | |||
| Borrowings from financial institutions | 705 | 220 | 1,071 |
| Government loans | 193 | 495 | 193 |
| Lease liabilities | 392 | 389 | 396 |
| Trade and other payables | 3,391 | 3,075 | 3,252 |
| Total current liabilities | 4,682 | 4,180 | 4,912 |
| Total liabilities | 11,400 | 11,034 | 11,946 |
| Total equity and liabilities | 27,096 | 30,847 | 28,998 |
Consolidated statement of changes in shareholders’ equity
| Equity attributable to owners of the parent company |
||||||
| In thousands of euro | Share capital |
Share premium | Reserve for invested non-restricted equity | Translation differences | Retained earnings | Total |
| Balance at January 1, 2022 | 80 | 504 | 38,526 | -88 | -21,970 | 17,052 |
| Comprehensive income | ||||||
| Loss for the financial year | -1,370 | -1,370 | ||||
| Other comprehensive income | ||||||
| Translation differences | -77 | -77 | ||||
| Total comprehensive income for the financial year |
-77 | -1,370 | -1,447 | |||
| Share options | 54 | 37 | 91 | |||
| Total transactions with owners of the company |
54 | 37 | 91 | |||
| Other adjustments | ||||||
| Balance at March 31, 2022 | 80 | 504 | 38,579 | -164 | -23,303 | 15,696 |
| Equity attributable to owners of the parent company |
||||||
| In thousands of euro | Share capital | Share premium | Reserve for invested non-restricted equity | Translation differences | Retained earnings | Total |
| Balance at January 1, 2021 | 80 | 504 | 37,470 | 166 | -18,147 | 20,073 |
| Comprehensive income | ||||||
| Loss for the period | -616 | -616 | ||||
| Other comprehensive income | ||||||
| Translation differences | -78 | -78 | ||||
| Total comprehensive income for the period | -78 | -616 | -694 | |||
| Share options | 237 | 111 | 348 | |||
| Total transactions with owners of the company | 237 | 111 | 348 | |||
| Other adjustments | 86 | 86 | ||||
| Balance at March 31, 2021 | 80 | 504 | 37,708 | 88 | -18,566 | 19,813 |
| Equity attributable to owners of the parent company |
||||||
| In thousands of euro | Share capital | Share premium | Reserve for invested non-restricted equity | Translation differences | Retained earnings | Total |
| Balance at January 1, 2021 | 80 | 504 | 37,470 | 166 | -18,147 | 20,073 |
| Comprehensive income | ||||||
| Loss for the period | -4,249 | -4,249 | ||||
| Other comprehensive income | ||||||
| Translation differences | -253 | -253 | ||||
| Total comprehensive income for the period | -253 | -4,249 | -4,502 | |||
| Share options | 1,055 | 340 | 1,395 | |||
| Total transactions with owners of the company | 1,055 | 340 | 1,395 | |||
| Other adjustments | 86 | 86 | ||||
| Balance at December 31, 2021 | 80 | 504 | 38,526 | -88 | -21,970 | 17,052 |
Consolidated cash flow statement
| In thousands of euro | Q1/2022 | Q1/2021 | 2021 |
| Cash flows from operating activities | |||
| Loss for the financial period | -1,370 | -616 | -4,249 |
| Adjustments: | |||
| Depreciation, amortization and impairment losses |
535 | 536 | 2,689 |
| Finance income and finance expenses | -73 | -7 | -472 |
| Other adjustments | 15 | 89 | 992 |
| Cash flows before change in net working capital | -893 | 2 | -1,041 |
| Change in net working capital: | |||
| Change in trade and other receivables (increase (-) / decrease (+)) |
425 | -600 | -1,409 |
| Change in inventories (increase (-) / decrease (+)) |
-303 | 209 | -340 |
| Change in trade and other payables (increase (+) / decrease (-)) |
117 | 169 | -22 |
| Cash flows before finance items | -654 | -221 | -2,811 |
| Interest paid | -11 | -18 | -66 |
| Other finance expenses paid | -23 | -18 | -64 |
| Interest received | 0 | 0 | 1 |
| Net cash from operating activities (A) | -688 | -257 | -2,94 |
| Cash flows from investing activities | |||
| Capitalization of development expenses | -542 | -436 | -2,112 |
| Acquisition of tangible assets | -317 | -121 | -462 |
| Net cash used in investing activities (B) | -859 | -557 | -2,574 |
| Cash flows from financing activities | |||
| Proceeds from share subscriptions | 54 | 237 | 1,012 |
| Proceeds from loans and borrowings | 0 | 0 | 1,366 |
| Repayment of loans and borrowings | -574 | -189 | -327 |
| Repayment of lease liabilities | -101 | -119 | -414 |
| Net cash from financing activities (C) | -622 | -71 | 1,637 |
| Net cash from (used in) operating, investing, and financing activities (A+B+C) | -2,169 | -884 | -3,876 |
| Net increase (decrease) in cash and cash equivalents | -2,169 | -884 | -3,876 |
| Cash and cash equivalents at beginning of period | 6,804 | 10,608 | 10,608 |
| Effect of movements in exchange rate on cash held | -5 | 43 | 73 |
| Cash and cash equivalents at end of period | 4,630 | 9,767 | 6,804 |
Selected notes
Corporate information and basis of accounting
Corporate information
Optomed is a Finnish medical technology group (hereafter ‘Optomed’ or ‘Group’) that specializes in handheld fundus cameras and solutions for screening of blinding eye diseases, established in 2004.
The Group’s parent company, Optomed Plc. (hereafter the ‘company’) is a Finnish public limited liability company established under the laws of Finland, and its business ID is 1936446-1. It is domiciled in Oulu, Finland and the Company’s registered address is Yrttipellontie 1, 90230 Oulu, Finland.
These interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and should be read in conjunction with Group`s last annual consolidated financial statements as at and for the year ended 31 December 2021. This Interim financial statements do not include all of the information required by IAS 34: selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group`s financial position and performance since the last annual financial statements.
Reportable segments
Q1/2022
| In thousands of euro | Devices | Software | Group admin | Total |
| External revenue | 1,065 | 2,150 | 0 | 3,214 |
| Net operating expenses | -424 | -601 | 0 | -1,025 |
| Margin | 641 | 1,549 | 0 | 2,190 |
| Depreciation and amortization | -365 | -157 | -2 | -524 |
| Other expenses | -1,140 | -1,135 | -853 | -3,127 |
| Operating result | -864 | 257 | -854 | -1,461 |
| Finance items | 0 | 0 | 71 | 71 |
| Loss before tax expense | -864 | 257 | -783 | -1,390 |
Q1/2021
| In thousands of euro | Devices | Software | Group admin | Total |
| External revenue | 1,447 | 2,494 | 0 | 3,944 |
| Net operating expenses | -605 | -762 | 0 | -1,367 |
| Margin | 846 | 1,731 | 0 | 2,577 |
| Depreciation and amortization | -384 | -152 | 0 | -536 |
| Other expenses | -1,073 | -1,194 | -624 | -2,891 |
| Operating result | -611 | 385 | -624 | -851 |
| Finance items | 0 | 0 | 216 | 216 |
| Loss before tax expense | -611 | 385 | -409 | -635 |
2021
| In thousands of euro | Devices | Software | Group Admin | Total |
| External revenue | 5,839 | 9,011 | 0 | 14,850 |
| Net operating expenses | -1,700 | -2,592 | 0 | -4,292 |
| Margin | 4,139 | 6,420 | 0 | 10,558 |
| Depreciation and amortization | -2,168 | -608 | -2 | -2,778 |
| Other expenses | -5,153 | -4,565 | -2,843 | -12,561 |
| Operating result | -3,182 | 1,247 | -2,844 | -4,780 |
| Finance items | 0 | 0 | 453 | 453 |
| Loss before tax expense | -3,182 | 1,247 | -2,392 | -4,327 |
Financial liabilities
| In thousands of euro | 31.3.2022 | 31.3.2021 | 31.12.2021 |
| Non-current financial liabilities | |||
| Borrowings from financial institutions | 3,646 | 3,299 | 3,813 |
| Government loans | 1,908 | 2,336 | 1,940 |
| Lease liabilities | 721 | 699 | 818 |
| Total | 6,275 | 6,334 | 6,571 |
| Current financial liabilities | |||
| Borrowings from financial institutions | 705 | 220 | 1,071 |
| Government loans | 193 | 495 | 193 |
| Lease liabilities | 392 | 389 | 396 |
| Trade payables | 841 | 686 | 944 |
| Total | 2,131 | 1,791 | 2,604 |
| Total financial liabilities | 8,406 | 8,125 | 9,175 |
Fair values – financial liabilities measured at amortized cost
Optomed considers that the carrying amounts of the financial liabilities measured at amortized cost substantially equal to their fair values.
Exposure to credit risk and loss allowance
Optomed considers it has heightened risk regarding Chinese customer’s trade receivables. The credit risk concentration has been formed and is associated with an increased credit loss risk due to overdue trade receivables. Chinese customer has paid its overdue receivable according to planned schedule.
| In thousands of euro | Gross carrying amount | Weighted av.
loss rate % |
Loss
allowance |
| At March 31, 2022 | |||
| Current (not past due) | 1,203 | 0.5 % | 6 |
| Past due | |||
| 1-30 days | 79 | 1.5 % | 1 |
| 31-60 days | 52 | 4 % | 2 |
| 61-90 days | 55 | 9 % | 5 |
| More than 90 days past due | 33 | 12 % | 4 |
| Specific loss allowance | 2,371 | 30 % | 711 |
| Total | 3,792 | 729 |
The year 2021 include a specific credit risk accrual of EUR 715 thousand which consist of overdue trade receivable from a Chinese customer.
| In thousands of euro | Gross carrying amount | Weighted av.
loss rate % |
Loss
allowance |
| At December 31, 2021 | |||
| Current (not past due) | 1,143 | 0.5 % | 6 |
| Past due | 0 | ||
| 1-30 days | 67 | 1.5 % | 1 |
| 31-60 days | 10 | 4 % | 0 |
| 61-90 days | 2 | 9 % | 0 |
| More than 90 days past due | 40 | 12 % | 5 |
| Specific loss allowance | 2,382 | 30 % | 715 |
| Total | 3,644 | 727 |